A Single Arm, Open-label, Phase II, Multicentre Study, to Assess the Safety of Vismodegib (GDC-0449) in Patient With Locally Advanced or Metastatic Basal Cell Carcinoma (BCC)

Trial Profile

A Single Arm, Open-label, Phase II, Multicentre Study, to Assess the Safety of Vismodegib (GDC-0449) in Patient With Locally Advanced or Metastatic Basal Cell Carcinoma (BCC)

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Vismodegib (Primary)
  • Indications Basal cell cancer
  • Focus Adverse reactions
  • Acronyms STEVIE
  • Sponsors Roche
  • Most Recent Events

    • 23 Oct 2017 Results of primary analysis (n=1215, data cut-off :16 Mar 2015), published in the European Journal of Cancer.
    • 02 Aug 2017 Results of pooled retrospective analysis of this and other 3 studies published in the Journal of the American Academy of Dermatology.
    • 24 Jul 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top